Telomerase-Mediated Telomere Targeting in Pediatric Cancers

October 17th - 20th, 2019



Chaired By

 Titia de Lange, Ph.D., Rockefeller University
 Jerry W. Shay, Ph.D., UT Southwestern


Important Dates

 08/17/2019 - Travel Form )
 09/17/2019 - Abstracts )


Venue Information

Hilton Denver Inverness
200 Inverness Drive West
Englewood, CO 80112
303.799.5800

www.hilton.com


Travel Agent Information

 Meeting #: Refer to your packet.
 Hours: 8:00am – 8:00 pm EST M-F
 Domestic: 669-210-8002
 International : 623-516-6140


About the Forbeck Foundation

 Forbeck Forum Information
 Travel Information
 General Program
 Frequently Asked Questions
 How to donate to this forum

Program Description

As humans age, the ends of linear chromosomes, telomeres, become progressively shorter. Short telomeres elicit a DNA damage response that leads cells to stop dividing and undergo senescence or apoptosis. This process inhibits the outgrowth of cancer cells that have undergone an abnormally high number of cell divisions. However, rare cancer cells can activate a cellular reverse transcriptase, telomerase, to reconstitute functional telomeres. Telomerase is absent in most normal tissues but is detected in the great majority of clinically detectable cancers. Thus, while telomerase is not oncogenic per se, it is almost universally required to permit the indefinite growth that occurs as part of cancer progression. Therefore, the inhibition of telomerase is an attractive target for cancer therapeutics. There have been several approaches to targeting telomerase in cancer in the past but none have advanced to late stage clinical trials. Thus, it is timely to review the progress and future directions for targeting telomerase in this Forbeck conference. Topics will include a discussion on why progress has been slow and how going forward this may change using new approaches. There will discussions on human genetic disorders affecting telomeres, alternatives to telomerase in a subset of tumors and the role of senescence as an initial brake preventing premalignant cells from progressing to advanced cancers.


Participant Information

Participant Institution
Mary Armanios, MD Johns Hopkins Medical Institute
Stephen Artandi, MD, PhD Stanford University
Floris Barthel, MD The Jackson Laboratory for Genomic Medicine
Rene Bernards, PhD Netherlands Cancer Institute
Allison Bertuch, MD, PhD Texas Children's Hospital
Simon Boulton, PhD Francis Crick Institute UK
Rochelle Buffenstein, PhD Calico Lab
Carla Daniela Robles-Espinoza, PhD International Laboratory for Human Genome Research
Titia De Lange, PhD Rockefeller University
Roger Greenberg, MD, PhD Univeristy of Pennsylvania
Dirk Hockenmeyer, PhD University of California, Berkeley
Marcin Imielinski, MD, PhD Weill Cornell Medicine
Jan Karlseder, PH.D. The Salk Institute
Joachim Lingner, Ecole Polytech Federale de Lausanne
Vicki Lundbald, The Salk Institute
Marta Markiwica-Potoczny, PhD University of Pittsburgh
Roderick O'Sullivan, PhD University of Pittsburgth Medical Center
Sharon Savage, MD National Institutes of Health
Agnel Sfeir, PhD New York University
Jerry Shay, PhD UT Southwestern
Enzo Tedone, PhD UT Southwestern
Tianpeng Zhang, PhD University of Pennsylvania

Airport Information

Denver International Airport (DEN) is the preferred airport as it is only 30 minutes from the meeting location.

  • Arrivals - Thursday at 1 PM, 3 PM and 6 PM
  • Departures - Sunday at 10 AM and 12 PM


Abstracts

The abstracts should be only one or two paragraphs outlining the theme of your presentation and should reflect the objective and spirit of the meeting (see above). Abstracts will be circulated about one week before the meeting. The meeting organizer will start requesting them a month before the meeting.


For more than 30 years, the Forbeck Foundation has proven to be an excellent steward of donor funds and has remained focused on executing its mission. Interested in sponsoring this Forum? Contact us today for more information!